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ABSTRACT 26
Several members of the tripartite motif (TRIM) family of E3 ubiquitin ligases regulate immune 27 pathways including the antiviral type I interferon (IFN-I) system. Previously, we demonstrated that 28 TRIM6 is involved in IFN-I induction and signaling. In the absence of TRIM6, optimal IFN-I signaling is 29 reduced, allowing increased replication of interferon-sensitive viruses. Despite having evolved 30 numerous mechanisms to restrict the vertebrate host's IFN-I response, West Nile Virus (WNV) 31
replication is sensitive to pre-treatment with IFN-I. However, the regulators and products of the IFN-I 32 pathway that are important in regulating WNV replication are incompletely defined. Consistent with 33 WNV's sensitivity to IFN-I, we found that in TRIM6 knockout (TRIM6-KO) A549 cells WNV replication 34
is significantly increased and IFN-I induction and signaling is impaired compared to wild-type (wt) 35 cells. IFNβ pre-treatment was more effective in protecting against subsequent WNV infection in wt 36 cells as compared to TRIM6-KO, indicating that TRIM6 contributes to the establishment of an IFN-37 induced antiviral response against WNV. Using next generation sequencing, we identified VAMP8 as 38 a potential factor involved in this TRIM6-mediated antiviral response. VAMP8 knockdown resulted in 39 reduced Jak1 and STAT1 phosphorylation and impaired induction of several ISGs following WNV 40 infection or IFNβ treatment. Furthermore, VAMP8-mediated STAT1 phosphorylation required the 41 presence of TRIM6. Therefore, the VAMP8 protein is a novel regulator of IFN-I signaling, and its 42 expression and function is dependent on TRIM6 activity. Overall, these results provide evidence that 43 TRIM6 contributes to the antiviral response against WNV and identified VAMP8 as a novel regulator 44 of the IFN-I system. 45
IMPORTANCE 47
WNV is a mosquito-borne flavivirus that poses threat to human health across large discontinuous 48 areas throughout the world. Infection with WNV results in febrile illness, which can progress to severe 49 neurological disease. Currently, there are no approved treatment options to control WNV infection. 50
Understanding the cellular immune responses that regulate viral replication is important in diversifying 51 the resources available to control WNV. Here we show that the elimination of TRIM6 in human cells 52 results in an increase in WNV replication and alters the expression and function of other components 53 of the IFN-I pathway through VAMP8. Dissecting the interactions between WNV and host defenses 54 both informs basic molecular virology and promotes the development of host-and viral-targeted 55 antiviral strategies. 56
INTRODUCTION 58
West Nile Virus (WNV) is an enveloped positive sense single stranded RNA virus and a member of 59 the family Flaviviridae (1, 2) . Mosquitoes competent for WNV (predominantly Culex) transmit the virus 60 through blood feeding (3) . Enzootic transmission cycles between birds and mosquitoes maintain the 61 virus in the environment, but mosquitoes also incidentally infect humans and other mammals that act 62 as dead-end hosts. In 1999, WNV was introduced to North America and has since then become an 63 endemic pathogen, causing annual outbreaks in human populations, and is the leading cause of 64 mosquito-borne encephalitis (4). Although primarily asymptomatic, WNV infection causes flu-like 65 symptoms in approximately 20% of infected humans with a fewer than 1% of symptomatic cases 66 progressing to neurologic manifestation (5) . The case fatality rate for symptomatic cases is 67 approximately 10% (1). Currently, no WNV vaccines or anti-viral treatments are approved for human 68 use (6) (7) (8) (9) (10) . 69
Understanding the molecular mechanisms of WNV replication at the host cellular level, and 70 specifically WNV-host type I interferon (IFN-I) interactions, may allow identifying targets for antiviral 71 development. Many groups have demonstrated that interferon-stimulated gene (ISG) products, such 72 as ISG54 (IFIT2) (11), IFITM3 (12) , and Oas1b (13) , and others (Reviewed in: (14) ) restrict WNV 73 replication. Further, in mouse models of WNV infection, lack of IFN-I induction through signaling 74 factors such as TLR3 (15), IRF7 (16), RIG-I (17), IFNβ (18), IFNAR (16), STAT1 (19) , and IKKε (11) 75 increases susceptibility to WNV. Mutations in IFN-I pathway genes and ISGs have also been 76 associated with increased disease during WNV infections in humans (20, 21) . Despite WNV's 77 sensitivity to IFN-I, WNV has evolved several mechanisms to antagonize IFN-I including NS1 78 interference with RIG-I and MDA5 function (22) , NS3 helicase impairment of Oas1b activity (13) , and 79 NS5 disruption of the type-I interferon receptor (IFNAR) surface expression (23), STAT1 80 phosphorylation (24), and sub-genomic flavivirus RNA (25). Since WNV's resistance to IFN-I contributes to virulence (16, 26) , defining the IFN-I signaling pathway components required to 82 respond to WNV infection is important in aiding the development of WNV-specific therapies. 83
Upon WNV infection, pathogen recognition receptors including RIG-I and MDA5 recognize viral RNA 84 (17) and signal through their adaptor MAVS to activate downstream IKK-like kinases TBK1 and IKKε. 85
Activation of TBK1 and IKKε promote IFN-I production through activation of transcription factors IRF3 86 and IRF7 (27). IFN-I is then secreted and engages the IFN-I receptor to induce IFN-I signaling. Early 87 in the IFN-I signaling cascade, the kinases Jak1 and Tyk2 phosphorylate STAT1 (Y701) and STAT2 88 (Y690), which dimerize and interact with IRF9 to form the ISGF3 complex (28, 29). ISGF3 then 89 translocates to the nucleus where it interacts with interferon-stimulated response element (ISRE) 90 present in the promoter of ISGs. In addition, upon IFN-I stimulation, IKKε plays an essential non-91 redundant role in phosphorylation of STAT1 on S708, which is required for induction of IKKε-92 dependent ISGs (30). Several IKKε-dependent ISGs, including ISG54 (30), are involved in restricting 93 WNV (11) . 94 TRIM6, an E3 ubiquitin ligase in the tripartite motif (TRIM) protein family, plays a crucial role in 95 facilitating the activation of the IKKε-dependent branch of the IFN-I signaling pathway (31) . In concert 96 with the ubiquitin activating (E1) enzyme and the ubiquitin conjugating (E2) enzyme, UbE2K, TRIM6 97 synthesizes unanchored K48-linked polyubiquitin chains that promote the oligomerization and 98 autophosphorylation of IKKε (T501) (31) . Following phosphorylation of T501, IKKε is activated and 99 phosphorylates STAT1 (S708) to promote the transcription of the IKKε-dependent ISGs (30, 31). Due 100 to TRIM6's role in activating IKKε-dependent IFN-I signaling and the importance of IKKε-specific ISGs 101 in restricting WNV, we hypothesized that WNV replication would be enhanced in the absence of 102 TRIM6. 103 Here we show that WNV viral load is increased and that IFN-I induction and IKKε-dependent IFN-I 104 signaling are impaired in TRIM6-knockout (TRIM6-KO) cells. Next-generation RNA sequencing 105 (NGS) identified several ISGs expressed at lower levels in TRIM6-KO cells compared to wild-type 106 (wt) cells, including several ISGs previously described to restrict WNV replication. In addition to ISGs, 107 the absence of TRIM6 also affects the expression of genes not known to regulate WNV replication of 108 IFN-I signaling, including Vamp8. We investigated the role of a TRIM6-dependent gene not previously 109 described to regulate WNV replication or IFN-I signaling, Vamp8. VAMP8 is a vesicle-associated-110 membrane protein in the SNARE (Soluble-N-ethylmaleimide-sensitive factor attachment protein) 111 family known to modulate endocytosis (32), exocytosis of secretory (33) (34) (35) (36) and lytic granules (37) , 112 thymus development (38) , receptor exocytosis (39) , and cross-presentation by antigen presenting 113 cells (40) . We found that VAMP8 does not directly affect WNV replication but promotes optimal IFN-I 114 signaling. Overall, we conclude that TRIM6 is important in promoting optimal IFN-I induction and 115 signaling during WNV infection and that VAMP8 is a novel TRIM6-dependent factor involved in 116 regulating IFN-I signaling.
117 118 RESULTS
WNV Replication is Increased in IFN-I Induction and Signaling Impaired TRIM6-KO Cells
120 To test our hypothesis that the absence of TRIM6 facilitates WNV replication, growth kinetics at 121 different multiplicity of infections (MOI) were determined in wt and TRIM6-KO A549 cells. A significant 122 increase in viral replication was detected in TRIM6-KO cells at 48 hours post-infection (h.p.i.) in 123 comparison to wt cells when infections were performed at both low (0.1 PFU/cell) and high (5.0 124 PFU/cell) MOIs ( Figure 1A -1B). To address the effect of the absence of TRIM6 on the IFN-I pathway, 125 protein expression and phosphorylation of IFN-I pathway components in WNV infected cells were 126 assessed ( Figure 1C ). Activation of both TBK1 and IKKε kinases are known to contribute to efficient 127 IRF3 phosphorylation and IFN-I induction. While the levels of phosphorylated TBK1 (S172), were 128 substantially higher in TRIM6-KO than in wt cells at late time points p.i. (Figures 1C, S1A ), the 129 TRIM6-dependent phosphorylation on IKKε-T501 was significantly attenuated in TRIM6-KO cells 130 (Figures 1C, S1C), as we previously reported in a model of Influenza infection (31) . Although less 131 striking, phosphorylation on IKKε-S172 was also reduced in TRIM6-KO cells (Figures 1C, S1B).
132 These data suggest that TRIM6 is important for promoting efficient activation of IKKε but not TBK1 in 133 the context of WNV infection.
134 Although the amount of pTBK1 (S172) is increased in TRIM6-KO cells, the phosphorylation of IRF3 135 (S386) is lower in TRIM6-KO compared to wt cells ( Figures 1C, S1D ), suggesting that TBK1 can not 136 completely compensate for reduced IKKε activity under these conditions of WNV infection. In line with 137 impaired IRF3 activation in TRIM6-KO cells, Ifnb mRNA levels were reduced in TRIM6-KO cells only 138 at early time points post-infection (6 hpi). However, the expression levels of Ifnb in TRIM6-KO cells, 139 significantly increased over time as compared to WT cells and correlated with the increased virus 140 titers at 48 h.p.i. ( Figure 1D ). Despite the increase in Ifnb mRNA levels at 48 hpi in TRIM6-KO cells, 141 the amount of secreted IFNβ protein was significantly decreased in TRIM6-KO compared to wild-type 142 cells ( Figure 1E ).
143 Consistent with reduced IFNβ protein accumulated in supernatants of infected TRIM6-KO cells, the 144 amount of pSTAT1 (Y701) is lower in TRIM6-KO cells compared to wt at all time points evaluated 145 (Figures 1C, S1E). In contrast, the expression of total STAT1 is substantially increased in TRIM6-KO 146 cells compared to wt, which is consistent with the reported accumulation of unphosphorylated STAT1 147 in IKKε-KO cells (41) . Phosphorylation on STAT1 (S708), an IKKε and TRIM6-dependent modification 148 (30, 31), is nearly undetectable in the TRIM6-KO cells upon WNV infection ( Figure 1C , S1F).
149 Consistent with this defect in the TRIM6-IKKε branch of the IFN-I signaling pathway in TRIM6-KO 150 cells, the TRIM6/IKKε-dependent ISGs Isg54 and Oas1 (30, 31), have different patterns of induction.
151 In the case of Isg54, induction is significantly lower in the TRIM6-KO cells than in wt cells at 24 hpi, 152 but this pattern is reversed at 72 hpi mirroring Ifnb expression ( Figure 1E ). In contrast, induction of 153
Oas1 is attenuated in TRIM6-KO cells 24-72 hpi ( Figure 1E ). IKKε-independent ISGs Irf7 and Stat1 154 and non-ISG Il-6 are expressed at higher levels in TRIM6-KO cells at later time points ( Figure 1E ), 155 again in correlation with Ifnb induction. As pIKKε (T501) plays a non-redundant role in facilitating the 156 expression of multiple ISGs (30, 31), that are known to be important in restricting WNV replication 157 (11, 13, 42) , the reduced capacity of TRIM6-KO cells to phosphorylate this residue likely contributes 158 to the impaired antiviral activity against WNV. Overall, the absence of TRIM6 augments WNV 159 replication and impairs the IKKε-dependent branch of the IFN-I pathway in line with our previous 160 findings with other viruses including Influenza (IAV), Sendai (SeV) and Encephalomyocarditis (EMCV) 161 (31). 162 163
IFN-I has reduced anti-WNV activity in TRIM6-deficient cells 164
Next, we sought to evaluate further the impact of TRIM6 on the antiviral efficiency of IFN-I against 165 WNV. Prior to infection, wt and TRIM6-KO A549 cells were treated with 100U of recombinant human 166 IFNβ for 4 hours prior to infection with WNV (MOI 5.0) for 24 hours (Figure 2 ). Pre-treatment with 167 IFNβ decreased viral load in both wt and TRIM6-KO cells, however IFN-I pre-treatment was 168 significantly less effective in inhibiting WNV replication in TRIM6-KO (40 fold) as compared to wt 169 controls (63 fold). As expected, this result indicates that IFN-I signaling is suboptimal in the absence 170 of TRIM6, enabling WNV to replicate to higher titers, and suggests that expression of TRIM6-171 dependent ISGs may be involved in establishing an optimal IFN-I mediated anti-WNV response.
172 173 VAMP8 is induced in a TRIM6-dependent manner
174
To identify other genes affected as a consequence of TRIM6's absence, next generation sequencing 175 (NGS) of mock ( Figure 3A ) and WNV-infected ( Figure 3B ) wt and TRIM6-KO cells was performed.
176 During WNV infection, canonical ISGs were identified as being expressed at lower levels in the 177 TRIM6-KO compared to wt cells, which validates the methodology ( Figure 3B ). Several canonical 178 ISGs down-regulated in TRIM6-KO cells have previously been described to inhibit WNV replication, 179 including Ifitm2 (42) and Ifitm3 (12) , or their loss of function is associated with increased WNV 180 susceptibility, including Mx1 (21, 43) and OasL (43) . We elected to investigate other genes not 181 previously described to regulate WNV replication or IFN-I pathways. One of the strongest 182 downregulated genes in both mock and infected cells, VAMP8, was chosen as a target for further 183 mechanistic validation ( Figure 3A-B ). Although VAMP8 has previously been noted to play an antiviral 184 role in response to Japanese encephalitis virus (JEV) (44), the mechanism has not been reported.
185 Further, VAMP8's described roles are diverse, but a connection to the antiviral IFN-I pathway has not 186 been described.
187 After confirming lower expression of VAMP8 at the translational ( Figure 3C ) and transcriptional 188 ( Figure 3D ) levels in TRIM6-KO cells, the role of VAMP8 in regulating WNV replication was 189 interrogated. Therefore, wt A549 cells were transfected with a VAMP8-targeting siRNA pool or non- 198 To further confirm whether VAMP8 is involved in regulation of the IFN-I signaling pathway in the 199 absence of virus infection, wt A549 cells were transfected with VAMP8-targeting or ntc siRNAs 200 followed by treatment with IFNβ for 16 hours. As expected, total STAT1 was induced in both VAMP8-201 and ntc-siRNA treated cells following IFNβ stimulation, but the level of total STAT1 in VAMP8-kd cells 202 was slightly attenuated ( Figure 4C ). VAMP8's effect on STAT1 activation is more evident; however, 203 with a strong reduction in the amount of pSTAT1 (Y701) ( Figures 4C, S2C ). To evaluate whether the 204 observed impairment in pSTAT1 (Y701) is specific to type-I IFN signaling, we treated ntc-and 205 VAMP8-kd cells with the type II interferon (IFNγ) for 16 hours. In contrast to the observed defect in 206 response to IFNβ, there was no detectable difference in pSTAT (Y701) between siControl and 207 siVAMP8-treated cells following IFNγ stimulation ( Figures 4D, S2D ). Consistent with a potential role 208 of VAMP8 in regulating STAT1 phosphorylation downstream of IFN-I signaling, mRNA expression 209 levels upon IFNβ treatment of ISGs including Isg54, Oas1, and Stat1 were significantly reduced in 210 VAMP8-kd as compared to controls in both A549 ( Figure 4E ) and a brain-derived cell line 211 (glioblastoma HTB-15 cells) ( Figure 4F ).
212 In an effort to determine whether VAMP8 functions at the level of STAT1 or upstream in the pathway, 213 we assessed the effects of VAMP8 on Jak1 activation, which is responsible for phosphorylation of 214 STAT1 on Y701. In the absence of VAMP8, phosphorylation of Jak1 (pY1034/1035) was reduced 215 compared to control cells ( Figures 4G, S2E ). Further, ectopic expression of FLAG-tagged VAMP8 in 216 HEK293T cells enhanced pJak1 following IFNβ stimulation compared to empty vector-transfected 217 cells ( Figure 4H, S2F) . Overall, the above evidence supports that 1) VAMP8 expression is TRIM6-218 dependent, 2) VAMP8 does not directly affect WNV replication, and 3) VAMP8 is involved in positive 219 regulation of IFN-I signaling on or upstream of Jak1 phosphorylation. 220 221 VAMP8 Knockdown Enhances WNV Replication in Cells Pre-treated with Type I IFN
222
Since VAMP8 modulates the IFN-I system, but does not appear to alter WNV replication, we 223 examined whether exogenous IFN-I pre-treatment would reveal a functional defect in IFN-I signaling 224 in VAMP8-kd cells during WNV infection. Prior to infection, wt A549 or brain-derived HTB-15 cells 225
were treated with siRNA (VAMP8 or ntc) followed by IFNβ treatment. Although IFNβ pre-treatment 226 reduced viral production in both groups, it was less efficient in protecting VAMP8-kd cells against 227 WNV replication as compared to ntc-cells (A549: ntc siRNA: 508 fold; VAMP8 siRNA: 79 fold ( Figure  228  5A) ; HTB-15: ntc siRNA: 430 fold; VAMP8 siRNA: 20 fold ( Figure 5B) ). As opposed to previous 229 experiments showing no impact on WNV replication following VAMP8-kd, the combination of IFN-β 230 pre-treatment and VAMP8 siRNA showed an 8-fold (A549) ( Figure 5A To further investigate whether VAMP8 overexpression can induce an anti-WNV response and 236 whether this requires the presence of TRIM6, we transfected wt or TRIM6-KO A549 cells with either 237 empty vector (pCAGGS) or FLAG-tagged VAMP8 (FLAG-VAMP8) 30 hours prior to infection with 238 WNV (MOI 5.0). As predicted, in wt A549 cells, the viral load was significantly decreased (8.5 fold) in 239 cells over-expressing FLAG-VAMP8 compared to empty vector control ( Figure 6A ). In contrast, when 240 FLAG-VAMP8 was over-expressed in TRIM6-KO cells the viral load was not significantly different 241 from cells transfected with empty vector ( Figure 6A ). This result suggests that VAMP8's attenuation of 242 WNV replication requires TRIM6 activity and can be explained by VAMP8's inability to compensate 243 for the defect in pSTAT1 (S708) in TRIM6-KO cells (Figure 6B, S3A ). This phosphorylation on S708 244 of STAT1 is required for stabilization of the ISGF3 complex (41) and induction of the complete set of 245 ISGs (30), including ISGs known to be involved in the anti-WNV response (11, 13, 42) . Therefore, 246 while VAMP8 is responsible for promoting STAT1-Y701 phosphorylation, which can only account for 247 limited antiviral effects, induction of the complete set of anti-WNV ISGs does not occur unless the 248 TRIM6-IKKε-STAT1-S708 arm of the pathways is active. To rule out a potential role of TRIM6 in 249
VAMP8-mediated promotion of STAT1-Y701 phosphorylation, we over-expressed FLAG-VAMP8 in 250 wt or TRIM6-KO A549 cells prior to treatment with IFNβ for 16 hours. Unexpectedly, over-expression 251 of VAMP8 induced pSTAT1 (Y701) following IFNβ stimulation in wt but not TRIM6-KO A549 cells 252 ( Figure 6C, S3B ), suggesting that TRIM6 is not only required for VAMP8 expression (as described 253 above in Figure 3 ), but also for VAMP8 activity. To further test this possibility, we investigated 254 whether TRIM6 interacts with VAMP8. Co-immunoprecipitation assays (coIP) showed that FLAG-255 VAMP8 co-precipitated HA-TRIM6 ( Figure 6D ) and HA-TRIM6 co-precipitated FLAG-VAMP8 in the 256 reverse coIP ( Figure 6E ). Taken together these data suggest that TRIM6 is important for VAMP8 257 expression levels as well as VAMP8 activity downstream the IFN-I receptor and for an optimal anti-258 WNV response.
259 260 DISCUSSION
261
Our study demonstrates the relevance of TRIM6 in regulating the IFN-I pathway during WNV infection 262 and identifies VAMP8 as a factor functionally involved in IFN-I signaling. Extensive research has 263 implicated the TRIM family of proteins in both regulation of the innate immune response and viral 264 replication (45-50). Specifically, TRIM6 has been shown to facilitate the formation of unanchored K48-265 linked polyubiquitin chains that provide a scaffold for IKKε binding, ultimately resulting in IKKε 266 activation and STAT1 phosphorylation at S708 (31) . Phosphorylation of STAT1 at S708 is important 267 to sustain IFN-I signaling and to express a unique subset of ISGs (30, 41). The relevance of IKKε-268 dependent gene expression has previously been described for WNV, and in the absence of ISG54 or 269 IKKε mice have an increased susceptibility (11) . These experiments served as a rationale for 270 exploring the functional role of TRIM6 during WNV infection.
271 As expected, we observed an increase in WNV replication in TRIM6-KO cells in parallel with 272 attenuated TRIM6-dependent activation of IKKε (T501 phosphorylation), IKKε-dependent STAT1 273 S708 phosphorylation, and IKKε-dependent gene expression. There was impaired Ifnb and Isg54 274 mRNA induction in TRIM6-KO cells at 6 and 24 hpi, respectively, but higher levels of induction at 72 275 hpi. The transient effect of TRIM6 on the IFN-I pathway may be related to the increase in pTBK1 276 (S172) in TRIM6-KO cells compensating for the impaired IKKε-dependent response to WNV infection.
277 Another possible explanation is that the ISGs higher in TRIM6-KO cells are either pSTAT1 (S708) 278 independent (STAT1 and IRF7, (30)) or can be induced directly via IRF3 or IRF7 by binding their 279 promoters (e.g. ISG54,(51)), while Oas1 is a TRIM6-IKKε-pSTAT1 (S708)-dependent ISG (30, 31) , 280 which is absent in TRIM6-KO cells. Further, redundant or alternative pathways not investigated here 281 may be enacted in the TRIM6-KO cells to control WNV replication. Although no other factor has been 282 shown to synthesize the unanchored K48-polyubiquitin chains required for IKKε activation, we cannot 283 exclude that other TRIM members or other E3-Ub ligases may compensate for the loss of TRIM6.
284 Alternatively, TRIM6 may play important roles in other pathways (i.e. NF-ĸB), resulting in cytokine 285 dysregulation and/or induction of IFNβ by TRIM6-independent pathways. Further, emergent WNV 286 strains encode a functional 2-O methylase in their non-structural protein 5 that prohibits IFIT proteins, 287 specifically murine ISG54 and human ISG58, from suppressing viral mRNA expression (52) . Since 288 WNV antagonizes components of this pathway, we cannot rule out the possibility that WNV proteins 289 target TRIM6 to impede IKKε-dependent expression of WNV-restricting ISGs. For example, the matrix 290 protein of Nipah virus (family Paramyxoviridae) works to promote the degradation of TRIM6 during 291 viral infection to promote viral replication through impaired IKKε signaling and thus a blunted IFN-I 292 response (46) . WNV protein antagonism of TRIM6 could also preclude observing more severe 293 differences in WNV replication between wt and TRIM6-KO cells. Alternatively, TRIM6 could play an 294 essential role in IKKε-dependent signaling but could also be hijacked by a virus to facilitate viral 295 replication. In a previous study, we showed that TRIM6 directly promotes the replication of ebolavirus 296 (family Filoviridae) through interactions with VP35 and that VP35 antagonizes TRIM6's capacity to 297 promote IFN-I signaling (45) .
298 Importantly, although the experiments presented here were performed with cell lines, our previous 299 published studies suggest that TRIM6 plays an important antiviral role via the IFN-I system in primary 300 human monocyte derived dendritic cells (hMDDC) and the antiviral response to two other viruses, 301 including SeV and EMCV, and to influenza virus in lungs of mice (31) . Therefore, the effects of TRIM6 302 are not restricted to cell line or to WNV.
303 Although we identified several ISGs differentially expressed in TRIM6-KO compared to wt cells 304 following WNV infection, we also identified Vamp8 to be significantly down-regulated under both 305 basal conditions and WNV infection. VAMP8 has not been previously described to affect WNV 306 replication or the IFN-I pathway. Although its role was not described, VAMP8 had been identified as 307 an antiviral factor in an siRNA screen for JEV, another mosquito-borne flavivirus (44). Here we 308 showed, in contrast to that seen with JEV, VAMP8 knockdown does not directly affect WNV 309 replication. The impairment of STAT1 Y701 phosphorylation during WNV in the VAMP8-kd cells lent 310 evidence that VAMP8 could be involved in IFN-I signaling. Since WNV efficiently impairs IFN-I 311 induction until nearly 24 hpi, VAMP8 depletion may not substantially impede of IFN-I signaling during 312 WNV infection in a tissue culture system. Evaluation of VAMP8's role in IFN-I signaling in the 313 absence of WNV infection revealed a striking impairment in STAT1 Y701 phosphorylation and a 314 modest inhibition of ISG gene expression in VAMP8-depleted cells. The impairment of STAT1 315 activation (pY701) in the absence of VAMP8 occurs specifically downstream of IFN-I but not IFN-II 316 signaling, and a delay and reduction of Jak1 activation may contribute to this phenotype. Further, 317 following IFNβ treatment, VAMP8-knockdown less efficiently inhibited WNV replication, which 318 provides support that VAMP8 mediates a functional step in the IFN-I signaling pathway. We also 319 showed that VAMP8 over-expression modestly inhibits WNV replication in wt but not TRIM6-KO cells, 320 which suggest that both VAMP8 and TRIM6 are necessary for induction of the full set of antiviral 321 ISGs. There are two possible explanations for these results; a) VAMP8 is important for efficient 322 phosphorylation on STAT1-Y701 (independent of STAT1-S708 phosphorylation by the TRIM6-IKKε 323 arm), and in parallel the TRIM6-IKKε arm is required for phosphorylation on STAT1-S708. Both of 324 these events are necessary for efficient induction of the full set of ISGs and antiviral activity, or b) 325 TRIM6 could be important for directly regulating VAMP8-mediated JAK1-STAT1-Y701 326 phosphorylation and activation, in addition to promoting IKKε-dependent STAT1-S708 327 phosphorylation. We favor the latter explanation because VAMP8 requires the presence of TRIM6 to 328 attenuate WNV replication ( Figure 6A ) and to induce IFN-dependent STAT1-Y701 phosphorylation 329 ( Figure 6C ). In addition, TRIM6 interacts with VAMP8 ( Fig 6D,E) , and TRIM6 deficiency impedes the 330 induction of STAT1-S708 phosphorylation independent of VAMP8 expression ( Fig 6B) .
331 Although our results suggest that TRIM6 and VAMP8 interact and VAMP8's regulation of the IFN-I 332 pathway is TRIM6-depedent, the detailed mechanism of how VAMP8 promotes JAK1 activation 333 downstream the IFN-I receptor is unknown. VAMP8 is involved in endocytosis (32), vesicle-vesicle 334 fusion (35) , and exocytosis (33, 34, 36) in various cell types including leukocytes (37, 40) , and various 335 secretory cells (33, 34, 36) including human lung goblet cells. As a vesicular SNARE (v-SNARE), 336 VAMP8 on the surface of a vesicle interacts with SNAREs on the target membrane surface to 337 facilitate membrane fusion (33, 35, 37) . Potential mechanisms of the IFN-I pathway, which VAMP8 338 may regulate, include surface expression of the IFNAR receptor or recycling of receptor components 339 to the plasma membrane. Although we did not find interaction of VAMP8 with the IFNAR or JAK1 340 (data not shown), it is still possible that VAMP8 could regulate JAK1 activity or IFNAR function. 341 VAMP8 has been described to regulate the surface expression of a water transport channel, 342 aquaporin 2, in the kidney (39) . Despite the reduced surface expression, the total amount of 343 aquaporin 2 is higher in the cell, but it is retained in vesicles below the plasma membrane (39) . 344
Alternatively, VAMP8 might influence the secretion of factors or the oxidative condition of the 345 microenvironment important to maintain IFN-I signaling. In phagocytic cells infected with Leishmania, 346 VAMP8 regulates the transport of NADPH oxidase to the phagosome to facilitate optimal conditions 347 for peptide loading into MHC class I molecules (40) . Although VAMP8 would not be regulating 348 phagocytosis in this model of WNV infection, it is possible that VAMP8 regulates NADPH oxidase 349 localization affecting the oxidative environment of the infected cell and consequently IFN-I signaling 350 (53) (54) (55) . TRIM6 may either directly affect VAMP8 expression or may act indirectly through a yet 351 unidentified secondary factor. Knowing that TRIM6 is important in regulating IKKε activation and 352 function (31), we assessed whether IKKε alters VAMP8 expression. There was no difference in 353 VAMP8 expression between IKKε-wt and -KO murine embryonic fibroblasts under basal conditions 354 ( Figure S4A ). We did identify two transcription factors, HNF4α and HNF4γ, with binding sites 355 upstream of VAMP8's transcription initiation site and within a VAMP8 intron that have significantly 356 lower gene expression in TRIM6-KO compared to wt A549 cells ( Figure S4B-D) . The expression of wt 357 TRIM6, but not the TRIM6 catalytic mutant (C15A), partially rescues the expression of VAMP8 in 358 TRIM6-KO A549 cells suggesting the presence of TRIM6 and its ubiquitin ligase activity are required 359 for VAMP8 expression ( Figure S4E ). Our study indicates a new role for VAMP8 in the IFN-I pathway, 360 which is regulated by TRIM6 during viral infection (Figure 7) . 361 Elucidating the interactions of the human immune system with viral infection is essential to 362 understanding viral pathology, as well as identifying cellular targets for antiviral drug development.
363 Our work has identified a novel IFN-I-related host factor that is important in the regulation of WNV 364 replication and in the life cycles of other viruses. This may provide a conserved target for the 365 development of anti-viral strategies and for the elucidation of further conserved pathways in host-366 pathogen interaction.
367 368
MATERIALS & METHODS 369
Viruses & Cells: West Nile Virus (WNV) isolate 385-99 was obtained from the World Reference 370 Center for Emerging Viruses & Arboviruses (UTMB, Dr. Robert Tesh). A549, HEK 293T, HTB-15 (U-371 118MG), and CCL-81 lines were obtained from the American Type Culture Collection. Wild-type and 372 IKBKE -/murine embryonic fibroblasts were a kind gift from Dr. tenOever at Ichan School of Medicine 373 at Mount Sinai, and were described previously (30, 31) . TRIM6 knockout cells were prepared as 374 previously described (45) . All lines were maintained in DMEM (Gibco), supplemented with 10% Fetal 375 Bovine Serum (Atlanta Biologicals). Infections were performed in DMEM supplemented with 2% Fetal 376 Bovine Serum (FBS), and 1% Penicillin/Streptomycin (Gibco). For growth kinetics experiments, 377 150,000 wt or TRIM6-KO A549 or HTB-15 cells/well were infected with 100μL of WNV multiplicity of 378 infection (MOI) 0.1 or 5.0 for 1 hour at 37°C, 5% CO 2 then the inoculum was removed and washed 3 379 times with 1mL of 1X PBS. After the cells were washed, 1mL of DMEM supplemented with 2% FBS 380 was added to each well. Supernatant (150μL) was collected at the designated time points for plaque 381 assay. Plaque assays were performed in 12-well plates containing 200,000 CCL-81 cells/well. Viral 382 samples were diluted log fold and applied to the monolayer. Following (56) . We used the human hg38 assembly as a reference with the UCSC 422 gene annotation file; both downloaded from the Illumina iGenomes website. The -quantMode 423 GeneCounts option of STAR provided read counts per gene, which were input into the DESeq2 424 (version 1.12.1) (57) differential expression analysis program to determine expression levels and 425 differentially expressed genes.
426 427 Transfections and Immunoprecipitations: Transient knockdown of endogenous VAMP8 in wt A549 428 was done in 12-well plates. Briefly, 20 pmol of Smartpool ON-TARGETplus Non-targeting (D-001810-429 10-05) or ON-TARGETplus VAMP8 (L-013503-00-0005) siRNA (Dharmacon) were transfected with 430 Lipofectamine RNAiMAX (Invitrogen) following the manufacturer's instructions. Cells were transfected 431 with siRNA 24 hours prior to infection or IFNβ treatment. The efficiency of VAMP8 knockdown was 432 monitored by qRT-PCR or western blot. Wild-type or TRIM6-KO A549 or HEK 293T cells were 433 transfected with 250ng of pCAGGS (empty vector) or FLAG-tagged VAMP8 (Origene) using 434 Lipofectamine 3000 (Invitrogen) according to the manufacturer's instructions. Cells were transfected 435 with plasmid DNA 30 hours prior to WNV infection or 24 hours prior to human IFNβ-1a treatment. For 436 immunoprecipitations, cells were lysed in RIPA complete buffer and centrifuged at 15,000 rpm at 4˚C 437 for 20 minutes to clarify the lysates. The clarified lysates were incubated with anti-HA or anti-FLAG 438 coated beads (Sigma) overnight at 4˚C. The beads were washed with RIPA (NEM + IA) seven times 439 then resuspended in 2X laemmli with 5.0% beta-mercaptoethanol and boiled at 100˚C for 10 minutes. 440 441 Western Blotting: Infected or IFNβ-treated cells were lysed in 2X Laemmli buffer with β-ME and boiled 442 at 100 o C for 10 minutes prior to removal from BSL-3. For immunoblotting, proteins were resolved 443 using SDS-polyacrylamide gel electrophoresis (4-15% SDS-PAGE) and transferred onto methanol-444 activated polyvinylidene difluoride (PVDF) membrane (Bio-Rad). The following primary antibodies 445 were used: anti-pIRF3 (S386) (1:1000) (Abcam), anti-total IRF3 (1:1000) (Immuno-Biological), anti-446 TRIM6 N-terminus (1:1000) (Sigma), anti-actin (1:2000) (Abcam), anti-pSTAT1 (Y701) (1:1000) (Cell 447 Signaling), anti-pSTAT1 (S708) (1:2000) , anti-total STAT1 (1:1000) (BD Biosciences), anti-VAMP8 448 (Cell Signaling) (1:500), anti-IKKε (T501) (1:1000) (Novus Biologicals), anti-IKKε (S172) (1:1000), 449 anti-total IKKε (1:1000) (Abcam), anti-pTBK1 (S172) (1:1000) (Epitomics), anti-total TBK1 (1:1000) 450 (Novus Biologicals), anti-total Jak 1 (BD Biosciences), and anti-pJak1 (Y1034/1035) (Cell Signaling).
451 Immunoblots were developed with the following secondary antibodies: ECL anti-rabbit IgG 452 horseradish peroxidase conjugated whole antibody from donkey (1:10,000), and ECL anti-mouse IgG 453 horseradish peroxidase conjugated whole antibody from sheep (1:10,000) (GE Healthcare; 454 Buckinghamshire, England). The proteins were visualized with either Pierce TM or SuperSignal ® West 455 Femto Luminol chemiluminescence substrates (Thermo Scientific). The amount of protein expressed 456 was determined using Fiji (58) to calculate the area under the curve. 457 458 IFNβ ELISA: Irradiated supernatants from WNV infected wt or TRIM6-KO A549 cells were collected at 459 8, 24, and 48 hpi to measure IFNβ using the VeriKine TM Human IFN Beta ELISA kit (pbl assay 460 science) following the manufacturer's instructions. Standards were used to generated a standard 461 curve to extrapolate the amount of IFNβ (pg/mL) in the supernatants. The limit of detection for the 462 assay is 50pg/mL. 
